



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	321096	UltraBiotic 45
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	31/07/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . UltraBiotic 45

Product Type	Single Medicine Product	Effective Date	31/07/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Relief of symptoms of medically diagnosed Irritable Bowel Syndrome
Linked indication - Maintain/support general health and wellbeing
Linked indication - Decrease/reduce/relieve abdominal pain/discomfort
Linked indication - Helps reduce occurrence of diarrhoea
Linked indication - Helps reduce occurrence of constipation
Maintain/support healthy digestive system function
Aid/assist digestion of lactose
Maintain/support digestive system health
Maintain/support intestinal good/beneficial/friendly flora
Helps maintain/support good/beneficial/friendly gut flora during antibiotic use
Help restore good/beneficial/friendly gut flora after antibiotic use
Decrease/reduce/relieve abdominal bloating/distention
Maintain/support immune system health
Maintain/support healthy immune system function

Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.
Label statement: If symptoms persist, talk to your health professional.
Label statement: If symptoms persist or worsen talk to your medical practitioner.
Product presentation must only refer to medically diagnosed IBS.
Label statement: Drink plenty of water (or words to that effect).



Australian Government
Department of Health
 Therapeutic Goods Administration

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.

Product presentation must not refer to or imply weight loss.

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Bifidobacterium animalis ssp lactis	4.275 billion CFU
Bifidobacterium bifidum	225 million CFU
Bifidobacterium breve	1.35 billion CFU
Lactobacillus acidophilus	7.4 billion CFU
Lactobacillus casei	9.45 billion CFU
Lactobacillus fermentum	1.35 billion CFU
Lactobacillus plantarum	3.15 billion CFU
Lactobacillus rhamnosus	15.55 billion CFU
Streptococcus thermophilus	2.25 billion CFU

Other Ingredients (Excipients)

- ascorbic acid
- dibasic potassium phosphate
- disodium edetate
- gellan gum
- hypromellose
- magnesium stearate
- maltodextrin
- microcrystalline cellulose
- monobasic potassium phosphate
- potable water
- potassium acetate
- silicon dioxide
- sodium chloride
- sucrose
- trehalose dihydrate

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary